Cisplatin/Carboplatin, Etoposide, and Vinorelbine in Advanced Lung Cancer
Author Information
Author(s): P Comellal, G Frascil, G De Cataldis, N Panza, R Cioffi, C Curcio, M Belli, A Bianco, G Ianniello, L Maiorino, M Della Vittoria, J Perchard, G Comellal
Primary Institution: National Tumor Institute of Naples
Hypothesis
We hypothesised a 15% minimum increment in the response rate with the experimental regimen over the 25% expected activity rate of the standard regimen.
Conclusion
The experimental regimen does not improve the prognosis of advanced NSCLC patients in terms of response rate and overall survival.
Supporting Evidence
- 15 responses were observed in arm A (28%) and 13 in arm B (25%).
- Median survivals were similar in the two arms (31 vs 27 weeks).
- Treatment did not affect the response rate significantly.
- Stage IV and performance status 2 were significantly associated with a lower probability of response.
- Four treatment-related deaths were registered in arm B compared to one in arm A.
Takeaway
Doctors tested a new combination of drugs for lung cancer but found it didn't work better than the standard treatment.
Methodology
A multicentre randomised phase III trial comparing two chemotherapy regimens in patients with advanced non-small-cell lung cancer.
Potential Biases
There was an imbalance in histological subtypes between treatment groups.
Limitations
The trial was stopped early due to a lower response rate in the experimental arm compared to the control.
Participant Demographics
Nearly 90% of patients were men, with more than 40% having poor performance status and over half having stage IV disease.
Statistical Information
P-Value
0.036
Confidence Interval
95% CI = 17-42 for arm A, 95% CI = 13-37 for arm B
Statistical Significance
p=0.036
Want to read the original?
Access the complete publication on the publisher's website